grant
Breast Cancer Brain Metastasis Therapy by Focused Ultrasound-Guided Control of HER2 CAR T cells
Organization GEORGIA INSTITUTE OF TECHNOLOGYLocation ATLANTA, UNITED STATESPosted 8 Jun 2023Deadline 31 May 2028
NIHUS FederalResearch GrantFY2025AddressAlgorithmsAnimalsAntigen ReceptorsAntigensAntitumor ResponseBBB permeabilizationBBB permeableBenchmarkingBest Practice AnalysisBleedingBrainBrain MetastasisBrain NeoplasiaBrain NeoplasmsBrain Nervous SystemBrain TumorsBreast CancerBreast Cancer CellBreast Cancer PatientBreast Cancer TreatmentBreast Tumor PatientCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD3CD3 AntigensCD3 ComplexCD3 moleculeCancer RelapseCell BodyCellsClinicClinicalClinical TrialsDiseaseDisorderDoseDrug DeliveryDrug Delivery SystemsERBB2ERBB2 geneEncephalonEngineeringFever TherapyFocused UltrasoundFocused Ultrasound AblationFocused Ultrasound TherapyFocused Ultrasound TreatmentGrantGranzymeHER -2HER-2HER2HER2 GenesHER2/neuHematopoietic Cell TumorHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHemorrhageHigh Power Focused UltrasoundHigh-intensity focused ultrasoundHumanHyperthermiaImmune systemIn VitroInduced HyperthermiaInfiltrationIntratumoral heterogeneityIntravenousLigandsMDA-MB-468MR ImagingMR TomographyMRIMRIsMagnetic ResonanceMagnetic Resonance ImagingMalignant Breast NeoplasmMalignant Hematopoietic NeoplasmMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMetastatic Neoplasm to the BrainMetastatic Tumor to the BrainMetastatic breast cancerMetastatic malignant neoplasm to brainMethodsMiceMice MammalsModelingModern ManMurineMusNEU OncogeneNEU proteinNMR ImagingNMR TomographyNuclear Magnetic Resonance ImagingOKT3 antigenOncogene ErbB2OutcomePatientsPerfusionPermeabilityProductionProliferatingProtocolProtocols documentationRelapseReportingSkullSolid NeoplasmSolid TumorSonicationStaining methodStainsSwitch GenesT cell infiltrationT cell responseT cells for CART-Cell Homing ReceptorsT3 AntigensT3 ComplexT3 moleculeTKR1TechnologyTestingTherapeuticTherapeutic HyperthermiaTherapeutic InterventionThermotherapyToxic effectToxicitiesTransgenic MiceTransgenic OrganismsTranslationsTreatment EfficacyTreatment ProtocolsTreatment RegimenTreatment ScheduleTumor CellXenograft ModelZeugmatographyanti-tumor responsebenchmarkbi-specific T cell engagerbispecific T cell engagerblood cancerblood lossblood-brain barrier permeabilizationblood-brain barrier permeablebloodbrain barrier permeabilizationbloodbrain barrier permeablebrain micrometastasisbreast tumor cellc-erbB-2c-erbB-2 Genesc-erbB-2 Proto-Oncogenescancer of bloodcancer of the bloodchimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsclinical hyperthermiaclinical relevanceclinical translationclinically relevantclinically translatablecombatcraniumcytotoxicdetermine efficacyeffective therapyeffective treatmentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationengineered T cellserbB-2 Genesevaluate efficacyexamine efficacygenetically engineered T-cellsherstatinheterogeneity in tumorshyperthermia therapyhyperthermia treatmentimage guidanceimage guidedimage guided therapyimmunogenimprovedindividuals with breast cancerintervention efficacyintervention therapyintra-tumoral heterogeneityintratumor heterogeneitylymphocyte pore-forming proteinmalignant breast tumormembermetastatic breast tumormetastatic mammary cancermetastatic mammary tumormigrationminimally invasivemouse modelmurine modelneoplastic cellnerve cell deathnerve cell lossneu Genesneuron cell deathneuron cell lossneuron deathneuron lossneuronal cell deathneuronal cell lossneuronal deathneuronal lossnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachpatients with breast cancerperforinperson with breast cancerpre-clinical evaluationpre-clinical studypreclinical evaluationpreclinical studyresponsesafety assessmentskin burnsystemic toxicitytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic efficacytherapy efficacytraffickingtransgenictransgenic T- cellstranslationtumortumor heterogeneitytumors in the brainxenograft transplant modelxenotransplant model
Description preview
Project Summary
HER2-targeted therapies are promising treatment options for metastatic breast cancer and have improved the
median overall survival. However, breast cancer brain metastasis (BCBM), which is observed in up to 50% of
HER2-positive breast cancer patients, continues to be a clinical challenge with most patients surviving less than
2…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click